Intellia Therapeutics Executive Compensation Details Released
Ticker: NTLA · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1652130
Sentiment: neutral
Topics: executive-compensation, DEF14A, equity-awards
TL;DR
Intellia's 2024 exec pay details are out - equity awards, fair value changes, and adjustments are all in the DEF 14A.
AI Summary
Intellia Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, changes in fair value of outstanding awards, and adjustments excluding certain reported values for both executive and non-executive personnel. Specific dollar amounts and dates related to these compensation components are outlined within the filing.
Why It Matters
This filing provides transparency into how Intellia Therapeutics compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal significant details about executive compensation and corporate governance that may impact investor sentiment and stock performance.
Key Numbers
- 2024 — Fiscal Year (Compensation data pertains to this year.)
- 20250430 — Filing Date (Date the DEF 14A was submitted.)
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0000950170-25-061023 (filing_id) — Accession Number for the filing
- 20250430 (date) — Filing Date
- 20250611 (date) — Period of Report
- 1231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing for Intellia Therapeutics, Inc.?
The primary purpose is to provide detailed information regarding the compensation of the company's named executive officers and directors for the fiscal year ending December 31, 2024, as well as other corporate governance matters.
What specific types of compensation are detailed in the filing for the fiscal year 2024?
The filing details equity awards, changes in the fair value of outstanding and unvested equity awards granted in prior years, and adjustments to equity awards.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted on April 30, 2025.
What is the fiscal year end for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc.'s fiscal year ends on December 31.
Does the filing distinguish between compensation for executive and non-executive personnel?
Yes, the filing includes sections and data points related to 'PeoMember' (likely referring to principal executive officers) and 'NonPeoNeoMember', indicating a distinction between executive and potentially other key personnel compensation.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Intellia Therapeutics, Inc. (NTLA).